Mobile App for Symptoms Monitoring in Cancer Patients: a Pilot Study

NCT ID: NCT04572282

Last Updated: 2021-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-01

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With the growing number of cancer survivors, challenges to deal with comorbidities and impacted quality of life of cancer survivors by the disease and treatments also surge. Symptoms and Adverse Events are common and insufficiently monitored in real time / real life, which leads to increased symptom burden, treatment delays and unplanned hospital admissions. Remote monitoring apps have been shown to improve quality of life, symptom control and survival in published clinical trials, but no data with such interventions exists on the Portuguese population.

We will conduct a pilot study to explore the feasibility of a mobile app for remote symptom monitoring in cancer patients. Patients will be recruited in Portuguese hospitals and will be invited to test the app for one month. Patient experience and satisfaction will be assessed via a weekly survey.

The results of this pilot study will inform subsequent randomized clinical trials to test safety and efficacy of remote monitoring and lifestyle interventions to improve symptoms control and quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single cohort study on cancer patients to explore the feasibility of mobile app for symptom monitoring and inform future randomized clinical trials and implementation. Patients will be screened at oncology visits for inclusion criteria and will be invited to use a mobile app to monitor and track treatment side-effects.

We will recruit a minimum of 10 cancer patients under systemic anti-neoplasic treatment being followed in medical oncology departments in portuguese hospitals. between February 1st and March 30th.

Participants will be invited to register their treatment side effects and symptoms on a health app designed for this purpose.

The Mentora Health App include a PRO-CTCAEâ„¢ based tool (a patient-reported outcome measurement system developed by the National Cancer Institute), version 1.1, that includes 80 symptoms (attachment 1) and has been translated and validated to Portuguese (Portugal) by the authoring entity. These symptoms are graded on a five-point scale from 0 (not present) to 4 (disabling) based on clinical criteria.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Symptoms and Signs Quality of Life Chemotherapeutic Agent Toxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mentora

Remote symptoms monitoring with mobile app

Group Type EXPERIMENTAL

Mentora app

Intervention Type DEVICE

Remote monitoring mobile app

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mentora app

Remote monitoring mobile app

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adults (18 years old or older)
* with a cancer diagnosis at any stage of any primary tumor (solid or hematologic)
* in systemic oncologic treatments of any type (including but not limited to immunotherapy, chemotherapy and targeted therapies) expected to continue for at least 4 weeks after enrolment, except when single treatment with hormone therapy for prostate cancer or breast cancer
* fluent in written Portuguese
* with a personal mobile smartphone (android or iphone)
* willing to give informed consent for study participation

Exclusion Criteria

* Cognitive impairment or disability that limits capacity to comply with study interventions and assessments as per attending physician's evaluation
* Having a life expectancy \< 3 months as determined by the attending oncologist ECOG performance status greater than 2
* Unable to read and comprehend written portuguese language
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Associacao de Investigacao de Cuidados de Suporte em Oncologia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Catarina Ribeiro

Role: PRINCIPAL_INVESTIGATOR

Associacao de Investigacao de Cuidados de Suporte em Oncologia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Catarina Ribeiro, MD, MSc

Role: CONTACT

+351962079292

Filipa Silva

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Improving Care After Chemotherapy
NCT01944137 COMPLETED NA